Nightfood Holdings Inc. (OTCQB: NGTF), operating through its TechForce Robotics subsidiary, announced the advancement of Phase 2 objectives under its joint development collaboration with Oncotelic Therapeutics (OTCQB: OTLC). The milestone is marked by the deployment of PUR-E, an autonomous clean room support robot, within SAPU Bio’s OEB-5 sterile injectable cGMP facility. This expansion moves beyond Phase 1 materials logistics operations into sterile manufacturing and clean room environments, where TechForce and Oncotelic are evaluating robotics, automation and AI-driven technologies to support regulated pharmaceutical workflows.
PUR-E joins TechForce’s LIM-E autonomous GMP support robot at the SAPU Bio facility. Together, these systems are being used to assess opportunities in sterile manufacturing operations, electronic batch record processes and other cGMP activities. According to the companies, the initiative is part of a broader effort to develop robotics and automation solutions for pharmaceutical manufacturing, biotechnology and life sciences environments. PUR-E operates as part of TechForce’s Robotics-as-a-Service Provider (RaaSP) platform.
This deployment is significant for the pharmaceutical industry as it demonstrates the integration of robotics and AI into highly regulated sterile manufacturing environments, which traditionally rely on manual processes. The use of autonomous robots like PUR-E and LIM-E can enhance operational efficiency, reduce contamination risks, and improve workflow consistency in clean rooms. For investors, this development signals Nightfood Holdings’ continued expansion into high-growth automation markets, particularly in life sciences, where demand for precision and compliance is paramount.
Nightfood Holdings, doing business as TechForce Robotics, is an AI-enhanced robotics and automation company focused on intelligent automation solutions across multiple industries. The company delivers its solutions through a Robotics-as-a-Service (RaaS) model, providing flexible, scalable automation while generating recurring revenue. As it expands into pharmaceutical automation and other high-precision applications, Nightfood leverages strategic partnerships and advanced engineering capabilities to accelerate innovation and commercialization.
For more information, see the full press release at https://ibn.fm/mXU1p. Updates on NGTF are available at http://ibn.fm/NGTF.
